Furthermore, formononetin supplemented the effect of sunitinib, a receptor tyrosine kinase inhibitor that targets VEGFR2, on tumor growth inhibition through largely decreasing the invasiveness of cancer cells stimulated by tumor growth in vivo through the fibroblast growth factor receptor 2 (FGFR2)-mediated AKT signaling pathway, attenuating tumor growth and angiogenesis [121,157]. Here, FGFR2 is linked to neoplasm.